The disease of cancer is usually attacked at time of diagnosis, and even chemoprevention is not usually considered until adulthood. Our hypothesis is that v^indows of development hold the key for chemoprevention of prostate cancer. We have previously demonstrated that genistein is bioavailable to the rat prostate and that lifetime exposure to physiological concentrations of genistein suppressed the development of chemically-induced prostate cancer. The purpose of our research is to determine if there is a developmental window for this chemoprevention and the mechanism (s) of chemoprevention. The importance of this Ues in the need to know, prior to initiation of human trials, if we need to expose infants and/or adults to get maximum chemoprevention. We have proposed to accomplish this in a dietary model at "physiological concentrations". To date, we have demonstrated that neonatal and prepubertal exposure to genistein via the diet does not alter development of the prostate buds in 21 and 35 day old rats. Chemoprevention experiments are in progress to determine the critical period ofexposure for protection against chemically-induced prostate cancer in rats.
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Introduction
The disease of cancer is usually attacked at time of diagnosis, and even chemoprevention is not usually considered until adulthood. Our hypothesis is that windows of development hold the key for chemoprevention of prostate cancer. We have previously demonstrated that Ufe-time exposure to physiological concentrations of genistein suppressed the development of chemicallyinduced prostate cancer. We have shown that genistein is bioavailable to the prostate. We have also demonstrated that genistein did not readily cross the placenta, hence we don't believe that the gestational period plays a significant role in the protective effect. On the other hand, it is primarily during the first weeks of postnatal life that prostate differentiation takes place, a period that may be influenced by genistein. The purpose of our proposed research is to determine if there is a developmental window for this chemoprevention and the mechanism (s) of chemoprevention. The importance of this hes in the need to know, prior to initiation of human trials, if we need to expose infants and/or aduhs to get maximum chemoprevention. We propose to accomplish this in a dietary model at "physiological concentrations".
Body
Aim 1. To determine if a specific window of development (prepubertal only, adult only or lifetime) is responsible for genistein chemoprevention of prostate cancer. This will be done on the following groups of rats. Group A) genistein via the diet from birth throughout Ufe to confirm that postnatal Hfetime exposure only protects against prostate cancer. Group B) genistein in the diet from birth until 35 days of age only. Group C) genistein in the diet starting at 90 days of age, 20 days after cancer initiation. Group D) no genistein in the diet as positive confrols.
This was to be initiated in the first year and to be completed in the second year. The breeders were purchased, the rats bred, freated with the carcinogenesis protocol, and exposed to genistein in the diet as listed above. The rats will be necropsied and the histopathology evaluations carried out in year 2.
Aim 2. To investigate prostate gland morphology in the dorsal and lateral lobes of the prostates of 21 and 35 day old rats exposed ± genistein in the diet, starting at birth. These data demonstrate that neonatal/prepubertal genistein in the diet does not alter prostate gland development. The significance of this will be revealed with the chemoprevention data (Specific Aim 1). Should we get prostate cancer chemoprevention with neonatal/prepubertal genistein exposure, this will suggest that genistein is not ahering prostate gland development as the cellular mechanism of chemoprevention.
Aim 3. To investigate the potential of genistein to regulate sex steroid receptor expression as mechanism of prostate cancer prevention. This is to be carried out during year 2. This work is already in progress.
Aim 4. To investigate DNA methylation of AR, ER alpha and ER beta as imprinting mechanism of action. This is to be carried out during year 3.
Key Research Accomplishments
Dietary genistein given during the neonatal and prepubertal periods did not alter cellular morphology of prostate development in 21 and 35 day old rats.
Reportable Outcomes
None.
Request for Modification
Budget: Ms. Natalie Durr has been the primary technician on this project, but she is leaving in August for pharmacy school. We intend to hire Mr. Glen Puckett as replacement for animal care and to assist with biological assays. Drs. Nadejda Lopatina and Jun Wang (25% each) will assist with necropsy, processing of tissues/tumors, and measurement of sex steroid receptor expression in the rat prostate. Dr. Eltoum's percent effort (10%) remains the same for histopathology. Dr. Lamartiniere's percent effort will be decreased to 15% effort to accommodate the budget. However, this will not compromise the work, especially with the addition of Dr. Lopatina to the project and the increased effort of Dr. Wang. The total personnel and fiinge budget remains the same, as does the total direct cost. I am enclosing a detailed second year budget that has same totals as the original budget. Also, enclosed is a copy of Dr. Lopatina's biographical sketch.
Conclusion
Neonatal/prepubertal genistein in the diet does not alter prostate bud perimeter in 21 and 35 day old rats. This demonstrates that genistein is not capable of ahering developmental of the rat prostate.
The work of Aim 2 is complete. Data from Aims 1 and 3 are expected in year 2. The work of this grant is progressing as outlined in the Statement of Work.
Appendices
The biographical sketch of Dr. Lopatina is enclosed. ^ 
